Combivent Related Published Studies
Well-designed clinical trials related to Combivent (Ipratropium / Albuterol)
Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. [2010.08]
Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. [2009.12]
Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. [2009.11]
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. [2005.05]
Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. [1997.08]
The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. [1997.02]
Well-designed clinical trials possibly related to Combivent (Ipratropium / Albuterol)
Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. [2011.01.11]
Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD. [2008]
Other research related to Combivent (Ipratropium / Albuterol)
Comparison of salbutamol and ipratropium bromide versus salbutamol alone in the
treatment of acute severe asthma. [2013]
Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease. [2010.03]
Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. [2009.09.06]
Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI *. [2009.03]
A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease. [2008.08]
Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. [2008.08]
Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. [2008.06]
The efficacy of nebulized albuterol/ipratropium bromide versus albuterol alone in the prehospital treatment of suspected reactive airways disease. [2005.10]
Other possibly related research studies
Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? [2003.06]
Generating monodisperse pharmacological aerosols using the spinning-top aerosol generator. [2006.09]
Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. [2008.07]
Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. [2009.01]
Salmeterol/fluticasone treatment reduces circulating C-reactive protein level in patients with stable chronic obstructive pulmonary disease. [2010.07]
Salmeterol/fluticasone treatment reduces circulating C-reactive protein level in
patients with stable chronic obstructive pulmonary disease. [2010]
|